

# Curriculum Vitae

## PERSONAL DATA

Family name : Hermawan  
First name : Adam  
Date of birth : 17.03.1983  
Place of birth : Wonosobo, Indonesia  
Nationality : Indonesia  
Postal address : Nongkosari 328 RT 01 RW 03 Kertek Wonosobo,  
Jawa Tengah, 56371  
E-mail address : adam\_apt@ugm.ac.id  
adam\_apt@yahoo.co.id  
adam.lmu@gmail.com

Home institution : Laboratory of Biochemistry and Molecular Biology,  
Department of Pharmaceutical Chemistry,  
Universitas Gadjah Mada  
Address : Building IV, Faculty of Pharmacy, Universitas Gadjah  
Mada, Sekip Utara II, Yogyakarta 55281, Indonesia.  
Telephone number : +62274 542907

Host institution : Pharmaceutical Biotechnology, Department of Pharmacy,  
Ludwig-Maximilians Universität (University of Munich)  
Address : Butenandtstr. 5-13, Building D 3.041, 81377, München  
Telephone number : +4989-2180-77468

## EDUCATION RECORDS

14.05.2012-16.07.2015

Doctoral degree, Pharmaceutical Biotechnology, Department of Pharmacy, Ludwig-Maximilians Universität, München. Supervisor : Prof. DI Dr. Ernst Wagner, Dr. Andreas Roidl  
PhD thesis : Molecular Evolution Assays Reveal Novel Targets and Mechanisms of Drug Resistance

13.09.2008-30.12.2009

Master of Pharmaceutical Science Degree, Faculty of Pharmacy, Gadjah Mada, Yogyakarta, Indonesia, Major in Drug Discovery and Development.  
Master thesis : Effect of Hesperidin in Doxorubicin Cytotoxicity on MCF-7 Breast Cancer Cells: Cell Cycle Modulation and Apoptosis Induction

12.09.2005-08.07.2006

Pharmacist degree, Faculty of Pharmacy Universitas Gadjah Mada, Yogyakarta, Indonesia,  
Major in Pharmaceutical Science and Industry

09.09.2001-26.07.2005

Bachelor of Pharmaceutical Science, Faculty of Pharmacy, Universitas Gadjah Mada,  
Yogyakarta, Indonesia, Major in Pharmaceutical Science and Industry

Bachelor thesis : Anticarcinogenic Effect of Benalu Belimbing (*Macrosolen cochinchinensis*  
(Lour.) Tiegh.) Leaves Water Extract to Female Mice Liver Induced by 7,12-dimethyl  
benz[a]anthracene (DMBA).

## **PUBLICATIONS**

Nisa F, **Hermawan A**, Murwanti R, Meiyanto E. Antiproliferative effect of gynura procumbens (lour.) Merr. Leaves etanolic extract on 7,12-dimethylbenz(a)anthracene induced male rat liver. *Adv Pharm Bull.* 2012;2(1):99-106. doi: 10.5681/apb.2012.014.

Meiyanto E, **Hermawan A**, Anindyajati. Natural products for cancer-targeted therapy: citrus flavonoids as potent chemopreventive agents. *Asian Pac J Cancer Prev.* 2012;13(2):427-36.

Nugroho AE, **Hermawan A**, Nastiti K, Suven, Elisa P, Hadibarata T, Meiyanto E. Immunomodulatory effects of hexane insoluble fraction of Ficus septica Burm. F. in doxorubicin-treated rats. *Asian Pac J Cancer Prev.* 2012;13(11):5785-90.

Nugroho AE, **Hermawan A**, Putri DD, Novika A, Meiyanto E, Kawaichi M. Combinational effects of hexane insoluble fraction of Ficus septica Burm. F. and doxorubicin chemotherapy on T47D breast cancer cells. *Asian Pac J Trop Biomed.* 2013;3(4):297-302. doi: 10.1016/S2221-1691(13)60066-0.

Putri H, Nagadi S, Larasati YA, Wulandari N, **Hermawan A**, Nugroho AE. Cardioprotective and hepatoprotective effects of Citrus hystrix peels extract on rats model. *Asian Pac J Trop Biomed.* 2013;3(5):371-5. doi: 10.1016/S2221-1691(13)60079-9.

Adina AB, Goenadi FA, Handoko FF, Nawangsari DA, **Hermawan A**, Jenie RI, Meiyanto E. Combination of Ethanolic Extract of Citrus aurantifolia Peels with Doxorubicin Modulate Cell Cycle and Increase Apoptosis Induction on MCF-7 Cells, *Iran J Pharm Res.* 2014;13(3):919-26.

## **PUBLICATIONS RELATED TO AK WAGNER LMU, MUNICH**

Kopp F, **Hermawan A**, Oak PS, Herrmann A, Wagner E, Roidl A. Salinomycin treatment reduces metastatic tumor burden by hampering cancer cell migration. *Mol Cancer*. 2014;13:16. doi: 10.1186/1476-4598-13-16.

Kopp F, **Hermawan A**, Oak PS, Ulaganathan VK, Herrmann A, Elnikhely N, Thakur C, Xiao Z, Knyazev P, Ataseven B, Savai R, Wagner E, Roidl A. Sequential Salinomycin Treatment Results in Resistance Formation through Clonal Selection of Epithelial-Like Tumor Cells. *Transl Oncol*. 2014 Dec;7(6):702-11. doi: 10.1016/j.tranon.2014.09.002.

Sommer A\*, **Hermawan A\***, Mickler F, Knyazev P, Bräuchle C, Wagner E, Ullrich A, Roidl A, Tamoxifen resistance of breast cancer cells is antagonized by Salinomycin treatment, submitted (\* equal contributions).

**Hermawan A**, Wagner E, Roidl A, Consecutive salinomycin pretreatment reduces drug efflux pump expression and chemoresistance of breast tumor cells against doxorubicin, research article, submitted.

**Hermawan A**, Wagner E, Roidl A, Emerging role of bone morphogenetic protein receptor II (BMP2) in cancer, review article, in preparation.

**Hermawan A**, Kopp F, Busse J, Herrmann A, Garcia-Roman J, Wagner E, Roidl A, Bone morphogenetic protein receptor II (BMP2) promotes doxorubicin-resistance in breast cancer cells, research article, in preparation.

von Schirnding C, **Hermawan A**, Weiß V, Feckl J, Bräuchle C, Wagner E, Roidl A, Engelke H, Bein T, Hybrid mesoporous apatite-citrate nanoparticles as platform for drug delivery applications with tunable toxicity against epithelial and mesenchymal cancer cells, research article, in preparation.

## **PARTICIPATION IN CONFERENCES**

**Hermawan A**, Kopp F, Busse J, Herrmann A, Garcia-Roman J, Ljepoja, Wagner E, Roidl A, Bone morphogenetic protein receptor II (BMP2) promotes doxorubicin-resistance in breast cancer cells, EACR-AACR-SIC Special Conference, Florence, Italy, 20-23 June 2015.

Tamoxifen Resistance Can Be Overcome By Salinomycin Treatment, Sommer A, **Hermawan A**, Mickler F, Knyazev P, Bräuchle C, Wagner E, Ullrich A, Roidl A, Interact Munich, 5-6 March 2015.

Tamoxifen Resistance Can Be Overcome By Salinomycin Treatment, Sommer A, **Hermawan A**, Mickler F, Knyazev P, Bräuchle C, Wagner E, Ullrich A, Roidl A, 23rd Biennial Congress of the European association for cancer research (EACR), 5-8 July 2014, Munich, Germany.

miR-27a is a functional biomarker for tamoxifen treatment of luminal A/B breast tumors, Ljepoja B, Garcia-Roman J, Bruno N, **Hermawan A**, Kopp F, Wagner E, Roidl A, 23rd Biennial Congress of the European association for cancer research (EACR), 5-8 July 2014, Munich, Germany.